Evommune schedules EVO570 webcast for November 5
EVO570 is investigational and has not been approved by any regulatory authority.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Evommune, Inc. (EVMN) announced a pre-recorded webcast on EVO570 and its immunology portfolio, scheduled for 8:30 a.m. ET on November 5, 2026. Management planned to discuss VAV1 biology, EVO570’s preclinical profile, its planned development path in rheumatoid arthritis, the transaction terms and its place in the pipeline. The webcast has no live question-and-answer session; an archived replay will remain available for 30 days after the event.
Under an exclusive license agreement previously announced with Hinova Pharmaceuticals Inc., Evommune has worldwide rights outside Greater China to develop, manufacture and commercialize EVO570, an oral VAV1-directed molecular glue degrader.
8-K Event Classification
Key Figures
Key Terms
molecular glue degrader technical
VAV1 medical
preclinical profile medical
T-cell and B-cell receptors medical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Is EVMN’s EVO570 approved?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure.
On November 5, 2026, the Company issued a press release announcing a live webcast on EVO570. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The Company will make available a copy of the presentation from the webcast on the News & Events page of the Company’s website at https://ir.evommune.com/news-events/ir-calendar.
The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number |
|
Description |
99.1 |
|
Press Release, dated November 5, 2026. |
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Evommune, Inc. |
|
|
|
|
|
Date: November 5, 2026 |
|
By: |
/s/ Luis Peña |
|
|
|
Luis Peña |
|
|
|
President and Chief Executive Officer |
2
Exhibit 99.1
Evommune to Host Webcast on EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
Management to discuss the in-licensing of EVO570, an oral VAV1-directed molecular glue degrader
PALO ALTO, Calif., NEW YORK, November 5, 2026 – Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that a pre-recorded webcast will be available at 8:30 a.m. E.T. today.
On the webcast, President and Chief Executive Officer Luis Peña and members of the management team will discuss EVO570, a potential best-in-class oral VAV1-directed molecular glue degrader. Evommune previously announced it has entered into an exclusive license agreement with Hinova Pharmaceuticals Inc. (SSE: 688302) granting Evommune worldwide rights outside of Greater China to develop, manufacture and commercialize EVO570 (formerly HC118 and known as HP570 in Greater China), an oral VAV1-directed molecular glue degrader (MGD). Management will cover the biology of VAV1, EVO570’s preclinical profile, the planned development path in rheumatoid arthritis, the terms of the transaction and how EVO570 fits within the Company’s broader immunology pipeline.
Webcast Information
The webcast will be available at 8:30 a.m. ET on Thursday, November 5, 2026, on the News & Events page of the Company’s website at https://ir.evommune.com/news-events/ir-calendar. An archived replay will remain on the website for 30 days following the event. The webcast will not include a live question-and-answer session; questions can be sent to the investor relations team.
About EVO570
EVO570 is an investigational, orally administered molecular glue degrader that directs VAV1 to the cell’s protein-disposal machinery for degradation. VAV1 expression is largely restricted to immune cells, where it acts as a key signaling protein downstream of both the T-cell and B-cell receptors. EVO570 is an investigational drug candidate and has not been approved by any regulatory authority.
About Evommune
Evommune, Inc. is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company’s mission is to improve patients’ daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, Evommune is advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation. For more information, please visit www.evommune.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential therapeutic benefits of EVO570, the planned development path of EVO570, and the continued development of the Company’s product candidates. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described under “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the SEC on March 5, 2026, as supplemented by its Quarterly Report on Form 10-Q filed with the SEC on August 6, 2026, and its other SEC filings. The Company disclaims any obligation to update these statements, except as required by law.
Contacts
Media and Investors:
Megan Humphreys
megan.humphreys@evommune.com